← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Cubist Pharmaceuticals, Inc.
Lexington, MA
$3,296,921
Total funding
7
Grants
Funding mix
By agency
NIH$3,296,921 · 7
By mechanism
R44$2,335,102 · 3
R43$961,819 · 4
Investigators at Cubist Pharmaceuticals, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Development of SecA as an Antimicrobial Target$530,161
R44 · FY2002 · AI
Modification of Daptomycin by Combinatorial Biosynthesis$500,000
R44 · FY2004 · GM
Development of SecA as an Antimicrobial Target$480,478
R44 · FY2001 · AI
BACTERIAL RIBONUCLEASE P INHIBITORS AS NOVEL ANTIBIOTICS$424,463
R44 · FY2000 · AI
Modification of Daptomycin by Combinatorial Biosynthesis$400,000
R44 · FY2005 · GM
Inhibitors of Bacterial Undecaprenyl DiphosphateSynthase$258,814
R43 · FY2002 · AI
Modification of daptomycin by combinatorial biosynthesis$258,205
R43 · FY2003 · GM
Structure activity relationships around lipopeptides$236,300
R43 · FY2003 · AI
Inhibitors of KD08-Phosphate Synthase as Antibiotics$208,500
R43 · FY2001 · AI